PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Hyojin Kim, Jin-Haeng Chung
J Pathol Transl Med. 2019;53(4):199-206.   Published online 2019 May 2     DOI: https://doi.org/10.4132/jptm.2019.04.24
Citations to this article as recorded by Crossref logo
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
Lee, Kim, Sung, Lee, Han, Kim, Choi
International Journal of Molecular Sciences.2019; 20(19): 4794.     CrossRef
Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers
João Lobo, Ângelo Rodrigues, Rita Guimarães, Mariana Cantante, Paula Lopes, Joaquina Maurício, Jorge Oliveira, Carmen Jerónimo, Rui Henrique
Cancers.2019; 11(10): 1535.     CrossRef
Basis of PD1/PD-L1 Therapies
Barbara Seliger
Journal of Clinical Medicine.2019; 8(12): 2168.     CrossRef
Do we need PD‐L1 as a biomarker for thyroid cytologic and histologic specimens?
Marc P. Pusztaszeri, Massimo Bongiovanni, Fadi Brimo
Cancer Cytopathology.2019;[Epub]     CrossRef